年轻初治急性髓系白血病应用索拉非尼的有效性和耐受性

Efficacy and Tolerability of Sorafenib for Patients of Younger and Newly Diagnosed Acute Myeloid Leukemia

1文献来源Rollig C,Serve H,Hüttmann A,et al.Addition of Sorafenib versus placebo to standard therapy in patients aged60 years or younger with newly diagnosed acute myeloidleukaemia（SORAML）：A multicentre,phase 2,randomised controlled tria[lJ].Lancet Oncol,2015,16（16）：1691-1699.2证据水平1b。3背景·目前急性髓系白血病（acute myeloidleukemia,AML）的标准治疗方案是阿糖胞苷联合葸环类或者蒽醌类药物，